DYN241220C65000
- 0.25
- 0.000.00%
Dyne Therapeutics Newsroom
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Dyne Therapeutics Analyst Ratings
J.P. Morgan Downgrades Dyne Therapeutics(DYN.US) to Hold Rating, Cuts Target Price to $35
Dyne Therapeutics Downgraded to Neutral From Overweight at JPMorgan
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Analysts' Top Healthcare Picks: 10x Genomics (TXG), Dyne Therapeutics (DYN)
Dyne Therapeutics Analyst Ratings
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Piper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Dyne Therapeutics Analyst Ratings
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics